MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Caladrius Biosciences Operating Income 2011-2025 | CLBS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Caladrius Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -25.7 M | -57.6 M | -29 M | -19.1 M | -20.1 M | -17 M | -27.6 M | -29.5 M | -114 M | -57.7 M | -36.8 M | -30.4 M | -34 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -17 M | -114 M | -37.2 M |
Quarterly Operating Income Caladrius Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.41 M | -4.87 M | -5.85 M | - | -5.34 M | -5.52 M | -6.6 M | - | -5.96 M | -6.88 M | -6.84 M | - | -37.7 M | -6.72 M | -6.62 M | - | -6.97 M | -7.15 M | -8.09 M | - | -5.35 M | -4.29 M | -4.06 M | - | -5.07 M | -5.35 M | -4.59 M | - | -3.76 M | -4.27 M | -5.16 M | - | -6.13 M | -7.71 M | -6.43 M | - | -5.73 M | -7.41 M | -11.1 M | - | -10.4 M | -25.7 M | -18.1 M | - | -16.3 M | -12.4 M | -13.5 M | - | -9.31 M | -8.17 M | -8.83 M | - | -8.09 M | -6.81 M | -7.54 M | - | -7.23 M | -10 M | -7.08 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.76 M | -37.7 M | -8.47 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
9.14 B | $ 223.01 | -0.99 % | $ 395 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-78.1 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
7.04 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
-56.8 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
ChromaDex Corporation
CDXC
|
7.73 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
-14.2 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Cellectar Biosciences
CLRB
|
-39 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Clovis Oncology
CLVS
|
-226 M | - | -7.23 % | $ 13 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.29 | -5.01 % | $ 631 M | Israel |
 |
Cortexyme
CRTX
|
-34.6 M | - | -1.05 % | $ 67.1 M | USA |
 |
Benitec Biopharma
BNTC
|
-9.83 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-536 M | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-34.4 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |